ARYx Therapeutics Inc represents values of innovation, commitment, and integrity. The company focuses on developing novel therapies to address unmet medical needs. With a patient-centric approach, ARYx Therapeutics Inc aims to improve the lives of individuals suffering from cardiovascular and metabolic diseases. By leveraging cutting-edge science and advanced technologies, the company strives to provide innovative treatment options. Guided by a strong corporate philosophy, ARYx Therapeutics Inc continuously seeks to enhance patient outcomes and contribute to the advancement of healthcare.

ARYx Therapeutics Inc primarily operates in the United States.

ARYx Therapeutics Inc has achieved several significant milestones in its history. Some of these include the development and approval of its lead product candidate, ARYx 214, for the treatment of atrial fibrillation. The company has also entered into strategic partnerships and collaborations with other pharmaceutical companies. Moreover, ARYx Therapeutics Inc has successfully completed clinical trials and received positive results, demonstrating the efficacy and safety of its products. These achievements highlight the company's dedication to advancing healthcare and its commitment to improving the lives of patients.

ARYx Therapeutics Inc is a pharmaceutical company that specializes in the discovery and development of innovative therapies for cardiovascular and gastrointestinal diseases. Founded in 1997 and headquartered in Fremont, California, ARYx Therapeutics has been actively engaged in research and development to address the unmet medical needs of patients. The company has a strong track record of advancing novel drug candidates through various stages of clinical development. With a dedicated team of scientists and industry professionals, ARYx Therapeutics strives to make a positive impact on patients' lives by providing effective and safe treatment options.

Some of the main competitors of ARYx Therapeutics Inc in the market include larger pharmaceutical companies such as Pfizer, GlaxoSmithKline, and Merck. These companies have a strong presence in the pharmaceutical industry and offer a wide range of products and therapies. However, ARYx Therapeutics Inc differentiates itself by focusing on developing innovative therapies and drugs that target specific medical conditions. By leveraging its expertise and strategic partnerships, ARYx Therapeutics Inc aims to carve out a niche in the market and provide unique solutions for patients.

ARYx Therapeutics Inc is primarily active in the pharmaceutical industry.

ARYx Therapeutics Inc is a pharmaceutical company focused on developing innovative therapies for various medical conditions. Their business model revolves around conducting research and development activities to create novel drug candidates targeting unmet medical needs. By leveraging their expertise in medicinal chemistry and drug design, ARYx Therapeutics aims to discover and develop effective treatments for diseases that have limited treatment options. Through strategic partnerships and collaborations, ARYx Therapeutics strives to bring their potential therapies to market, ultimately improving patient outcomes and addressing critical healthcare challenges.

Pašreizējais KGV ARYx Therapeutics nevar tikt aprēķināts.

KUV šobrīd ARYx Therapeutics nevar aprēķināt.

AlleAktien kvalitātes vērtējums ARYx Therapeutics ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu ARYx Therapeutics.

Pašlaik peļņa ARYx Therapeutics nevar tikt aprēķināta.

ARYx Therapeutics Inc is a biopharmaceutical company specializing in the development and commercialization of novel drugs. The company was founded in 1997 and is headquartered in Fremont, California, USA. The company's business model is based on the research and development of novel pharmaceutical preparations for the treatment of serious diseases. The company has a wide pipeline of products focused on various therapeutic areas, such as the treatment of chronic pain, heart disease, infections, and metabolic disorders. One of the company's main divisions is the research and development of new drugs. ARYx Therapeutics invests significant resources in the research and development of innovative pharmaceutical preparations. The company has a strong internal research department and works closely with leading scientific institutions around the world. The company also has an extensive R&D infrastructure that allows it to develop drug candidates from discovery to clinical development in-house. The company uses unique technologies and platforms to optimize its research and identify candidates faster and more efficiently. Another important division of the company is marketing and sales. ARYx Therapeutics works closely with leading pharmaceutical companies around the world to market and distribute its products. The company uses a differentiated distribution model that allows it to market its products widely and share revenue with other companies. The company also has a strong global presence and has subsidiaries in Europe and Asia. These subsidiaries are responsible for marketing and distributing ARYx products in their respective markets. In terms of products, ARYx Therapeutics offers a wide range of drug candidates, including AX-202, AX-301, AX-325, AX-426, AX-390, AX-768, and AX-844. These substances are currently in various stages of clinical development and target different types of diseases. For example, AX-202 is a drug candidate for the treatment of chronic pain and is currently in Phase II clinical trials. On the other hand, AX-325 is a drug candidate for the treatment of heart disease and is in preclinical development. In summary, ARYx Therapeutics is a leading biopharmaceutical company focused on the development of innovative pharmaceutical preparations for the treatment of serious diseases. With a wide pipeline of products, a strong R&D infrastructure, and a differentiated distribution strategy, the company is well positioned to achieve strong growth in the coming years.

ARYx Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt ARYx Therapeutics vai uzņēmums nedod dividendes.

ARYx Therapeutics ISIN ir US0433871094.

ARYx Therapeutics simbols ir ARYX.

Pēdējo 12 mēnešu laikā ARYx Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos ARYx Therapeutics plāno maksāt dividendes 0 USD apmērā.

ARYx Therapeutics pašreizējā dividendu rentabilitāte ir .

ARYx Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

ARYx Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

ARYx Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu ARYx Therapeutics apmērā 0 USD, kas tika izmaksāta 12.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 12.07.2024..

Pēdējās dividendes izmaksa notika 12.07.2024..

Gadā 2023, ARYx Therapeutics izmaksāja 0 USD dividendes.

ARYx Therapeutics dividendes tiek izmaksātas USD.